Randomized trial evaluates durable response rate in cancer immunotherapy, highlighting clinical utility in oncolytic virus therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kaufman et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: